Goldman Sachs Reaffirms Their Buy Rating on Alignment Healthcare (ALHC)

Goldman Sachs analyst Nathan Rich maintained a Buy rating on Alignment Healthcare (ALHCResearch Report) today and set a price target of $21.00. The company’s shares opened today at $17.85.

According to TipRanks, Rich is a 3-star analyst with an average return of 6.0% and a 56.90% success rate. Rich covers the Healthcare sector, focusing on stocks such as Idexx Laboratories, Zoetis, and Alignment Healthcare.

Alignment Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $20.29, representing a 13.67% upside. In a report released today, Bank of America Securities also maintained a Buy rating on the stock with a $23.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $23.35 and a one-year low of $6.14. Currently, Alignment Healthcare has an average volume of 436.5K.

Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALHC in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which they receive healthcare coverage and services on an annual basis.

Read More on ALHC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More